Peter Attia· MD
yeah I mean I'm a huge CBS egm advocate and really looking forward to what the next few years will bring when these things can become a lot more affordable and a lot more accessible
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
yeah I mean I'm a huge CBS egm advocate and really looking forward to what the next few years will bring when these things can become a lot more affordable and a lot more accessible
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
I certainly hope that there's a day and it's it's probably four years five years from now when the SI GM's are really tiny you've guys basically the size of a contact lens it's a tiny patch it's a you know 400 to 1000 micron needle that you just smack on your belly every day and you just dispose of it
I'm a huge CBC GM advocate and really looking forward to what the next few years will bring when these things can become a lot more affordable and a lot more accessible
Post-meal glucose spikes in non-diabetics drive long-term cardiometabolic disease independently of HbA1c.
Wearing a continuous glucose monitor leads to personalized dietary improvements that hold up beyond 12 weeks.
Continuous glucose monitors meaningfully change behavior in non-diabetic adults beyond the first month.
CGM use in metabolically healthy adults induces orthorexic-style dietary anxiety without health benefit.